Efficacy of Chinese Herbal Medicine to Prevent and Treat COVID-19 Close Contacts (CHM COVID-19)
Efficacy of Chinese Herbal Medicine to Prevent and Treat COVID-19 Close Contacts: A Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Zhaoxiang BIAN, MD, PhD
- Phone Number: +852 3411 6521
- Email: bzxiang@hkbu.edu.hk
Study Contact Backup
- Name: Linda Zhong
- Phone Number: +852 3411 6523
- Email: ldzhong@hkbu.edu.hk
Study Locations
-
-
Hong Kong
-
Hong Kong, Hong Kong, China
- School of Chinese medicine, Hong Kong Baptist University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Household contact exposure to individuals with SARS-CoV-2 infection
- Aged ≥18
- General healthy or have a chronic, stable medical condition
- Voluntarily signing a written informed consent form
- Able to follow written and oral instructions in Chinese
Exclusion Criteria:
- Moderate to severe symptomatic SARS-CoV-2 infection
- An allergic history to Chinese herbal drugs or a known allergy to the ingredients of the study drug
- Pregnancy, breastfeeding or plan to become pregnant within the study timeframe
- Vulnerable adults (i.e., mentally or physically disabled to take care of himself/herself)
- Any physical examination findings, and/or history of any illness, or concomitant medications that, in the opinion of the study investigator, might not be suitable to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment group
Chinese Herbal Medicine
|
Oral administration, twice per day.
Other Names:
|
|
No Intervention: Control group
usual care
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of subjects who have PCR confirmed SARS-CoV-2 infection
Time Frame: 3 weeks
|
3 weeks
|
|
Proportion of subjects with treatment-emergent adverse events (TEAEs) and severity of TEAEs
Time Frame: 3 weeks
|
3 weeks
|
|
Proportion of subjects who subsequently develop COVID-19 symptoms or signs
Time Frame: 3 weeks
|
3 weeks
|
|
Proportion of subjects who subsequently develop moderate to severe COVID-19 infection
Time Frame: 3 weeks
|
3 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of days of symptomatic PCR confirmed SARS-CoV-2 infection
Time Frame: 3 weeks
|
3 weeks
|
|
Number of days of PCR confirmed SARS-CoV-2 infection
Time Frame: 3 weeks
|
3 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Aiping Lyu, School of Chinese medicine, Hong Kong Baptist University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CHM COVID-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.